Navigation Links
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Date:7/20/2009

AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in the same patient, and is referred to as "metabolic syndrome." Low level inflammation and oxidative stress are the mechanistic underpinnings of metabolic syndrome.

The Cardax lead compound is a novel and highly bioavailable proprietary derivative of the natural dietary carotenoid astaxanthin that addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal studies with the Company's compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have also been documented along with a robust improvement in thrombosis and myocardial salvage.

The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the liver and the vasculature. Cellular studies have determined that this compound acts as a plasma and mitochondrial membrane stabilizer and a potent antioxidant.

"Cardax has pioneered a novel approach to treating the source of inflammation, intracellular oxidative stress," said David G. Watumull, CEO of Cardax. "We believe this to be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome."

"Our novel derivative of the natural carotenoid astaxanthin exhibits dramatically improved bioavailability relative to the parent compound," adds Chief Medical
'/>"/>

SOURCE Cardax Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
5. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
6. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
7. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
11. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).../-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/I...tiveRandomizedOralTherapyEvaluationinCrohn,sdiseas...derate-to-severeCrohn,sdiseasedemonstratedclinical....Thestudydemonstratedevidenceofclinicalefficacyint...creaseintheCrohn,sDiseaseActivityIndex(CDAI)inpati...
(Date:11/24/2009)... WHAT:RomHoubens,aBelgianmanthoughttohavebeenincom...yconsciousandawakeduringthattimeandwasthesubjectof...uredinthesegmenttoillustratehowpeoplewithLocked-in...,, WHEN:GoodMorningAmerica-- Tuesday,November24..., WHO:RomHoubenswasanengineeringstudentin1986whenh...
(Date:11/24/2009)...all/--QuestDiagnosticsIncorporated(NYSE: DGX ),the...ionandservices,announcedthatitisscheduledtospeakat...YorkCity.ThepresentationisscheduledforWednesday,De...conference,thecompanywillreaffirmits2009guidancefo...eed18%ofrevenues,anddilutedearningspersharefromcon...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Chromosomal problems affect nearly all human embryos 9081 1Chromosomal problems affect nearly all human embryos 9081 2Chromosomal problems affect nearly all human embryos 9081 3Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 1Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 2Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 3Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community 50494 4Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 1Siemens Hearing Instruments Introduces Affordable and Flexible Pure 300 50492 2
(Date:11/27/2009)...,Israel,Nov.27/PRNewswire-FirstCall/--ShamirOptica...roviderofinnovativeproductsandtechnologytotheophth...orshaddeclaredadividenddistributioninanaggregateam...edontheNovember25,2009representativerateofexchange...ontheNovember25,2009representativerateofexchange)p...
(Date:11/27/2009)... Voyant Health™ announced today that Spe... its TraumaCad Enterprise orthopedic templating so... , (PRWEB) November 27, 2...pectrum Health (Grand Rapids, Michigan) has licens...solution and its TraumaCad Extend workflow solutio...
(Date:11/26/2009)....,Nov.27/PRNewswire/--ThediabetespopulationintheUn...ualmedicalspendingonthediseaseisprojectedtohit$336...blishedintheDecemberissueof DiabetesCare .TheNatio...fNovoNordisk,commissionedtheanalysisbyateamfromthe...thenumberofAmericanslivingwithdiabeteswillrisefrom...
(Date:11/26/2009)... No more letters from the North Pole, Textsant...essages from Santa , Nort...rational efficiencies at the North Pole Santa Clau...en all over the globe informed of his Christmas pr...;s research department have identified a large and...
(Date:11/25/2009)...ov.25/PRNewswire-USNewswire/--Whenmostpeoplehearth...orcanalsogivepatientsthehelptheyneed.TMJstandsfort...dible)contacts/connectswithyourskull(temporalbone)...unctionarepainwithchewing,clickingorpoppingoftheja...nincluding:headaches,fatigue,sleepdisturbances,irr...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
..., Oct. 24 How many starving children,could you sa...://www.newscom.com/cgi-bin/prnh/20071024/NYW141 )...CEO of Diet Power, Inc.,His company has launched a...eight loss diet. Tell this new online computer th...
... 24 The ASPCA(R) (The American Society,for the Pr...nding to the,San Diego Humane Society for hay and ...k of devastating wildfires in California. (Logo: ...tragedy," said ASPCA President and CEO Ed Sayres.,...
...ould welcome a vaccine against the human papilloma...Quebec, Canada survey suggests. Research published...th shows that 91% of young women (18-25 year-olds)...Laval University hospital center in Quebec analyse...
... 24 It,s no shock that our insurance,premiums are...ose with,fixed incomes, the costs are particularly... Sloane explains. Listen to this report from AARP... and,photos for free and unrestricted use at http...
...Oct. 24 Kathleen M. Foley, MD,of Memorial Sloan-K... Fine,MD, of the University of Utah School of Medi...ucation and Leadership Award for 2007 at the 9th,A...ymptom management. The award and professional conf...
...r is often physicians, best strategy, experts say ... Serious medical errors don,t just affect the heal...tient,s relationship with his or her doctor, too, ...h -- or avoidance of -- the affected patient, say...
Other Medicine News:Health News:Lose Weight, Conquer World Hunger with www.DonateYourCalories.com 2Health News:ASPCA Provides Funding for Hay, Equine Expenses Following Outbreak of California Wildfires 2Health News:Two Physicians Recognized for Work in Pain and Symptom Management 2Health News:Doctor-Patient Bond Frays After Medical Mistake 2Health News:Doctor-Patient Bond Frays After Medical Mistake 3Health News:Doctor-Patient Bond Frays After Medical Mistake 4
KOWA Automated Tonometer KT-500
PCA II Pump
6060 MULTI-THERAPY Infusion Pump
AMS Reference Lab
Medicine Products: